Resmed Bull Sees Divestment Sharpening Strategic Focus

Dow Jones

Jul 08

0435 GMT - ResMed's bull at Morgans likes the divestment of its MatrixCare division for the way it sharpens the breath-tech provider's strategic focus. Analyst Derek Jellinek explains in a note that the US$490 million sale simplifies the investment case for dual-listed ResMed by exiting the somewhat peripheral vertical of aged care, and increasing its exposure to core franchises including sleep devices and masks. The divestment monetizes a mature asset and funds shareholder returns that should help support ResMed's share price, Jellinek tells clients. Morgans has a buy rating on ResMed's Australia-listed stock and a target price of 41.72 Australian dollars. Shares are down 0.3% at A$31.345. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

July 08, 2026 00:35 ET (04:35 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2649576449"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2649576449\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2649576449?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 12:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649576449","market":"other","top_or_hot":-1,"title":"Resmed Bull Sees Divestment Sharpening Strategic Focus","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0435 GMT - ResMed's bull at Morgans likes the divestment of its MatrixCare division for the way it sharpens the breath-tech provider's strategic focus. Analyst Derek Jellinek explains in a note that the US$490 million sale simplifies the investment case for dual-listed ResMed by exiting the somewhat peripheral vertical of aged care, and increasing its exposure to core franchises including sleep devices and masks. The divestment monetizes a mature asset and funds shareholder returns that should help support ResMed's share price, Jellinek tells clients. Morgans has a buy rating on ResMed's Australia-listed stock and a target price of 41.72 Australian dollars. Shares are down 0.3% at A$31.345. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2026 00:35 ET (04:35 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Resmed Bull Sees Divestment Sharpening Strategic Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResmed Bull Sees Divestment Sharpening Strategic Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-08 12:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0435 GMT - ResMed's bull at Morgans likes the divestment of its MatrixCare division for the way it sharpens the breath-tech provider's strategic focus. Analyst Derek Jellinek explains in a note that the US$490 million sale simplifies the investment case for dual-listed ResMed by exiting the somewhat peripheral vertical of aged care, and increasing its exposure to core franchises including sleep devices and masks. The divestment monetizes a mature asset and funds shareholder returns that should help support ResMed's share price, Jellinek tells clients. Morgans has a buy rating on ResMed's Australia-listed stock and a target price of 41.72 Australian dollars. Shares are down 0.3% at A$31.345. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2026 00:35 ET (04:35 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0170899867.USD","symbol_name":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2649576449","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649576449","pubTimestamp":1783485300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0435 GMT - ResMed's bull at Morgans likes the divestment of its MatrixCare division for the way it sharpens the breath-tech provider's strategic focus. Analyst Derek Jellinek explains in a note that the US$490 million sale simplifies the investment case for dual-listed ResMed by exiting the somewhat peripheral vertical of aged care, and increasing its exposure to core franchises including sleep devices and masks. The divestment monetizes a mature asset and funds shareholder returns that should help support ResMed's share price, Jellinek tells clients. Morgans has a buy rating on ResMed's Australia-listed stock and a target price of 41.72 Australian dollars. Shares are down 0.3% at A$31.345.  Dow Jones NewswiresJuly 08, 2026 00:35 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4567":"ESG概念","BK4082":"医疗保健设备","BK4585":"ETF&股票定投概念","LGHT":"LANGAR GLOBAL HEALTHTECH ETF","BK4548":"巴美列捷福持仓","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","RMD.AU":"Resmed DRC","BK7007":"医疗保健设备","RMD":"瑞思迈","BK7501":"新冠治疗股","BK4504":"桥水持仓","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","BK4588":"碎股"},"translate_title":"瑞思迈公牛认为撤资将增强战略重点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGHT":0.6,"RMD":0.9,"RMD.AU":0.9},"content_text":"0435 GMT - ResMed's bull at Morgans likes the divestment of its MatrixCare division for the way it sharpens the breath-tech provider's strategic focus. Analyst Derek Jellinek explains in a note that the US$490 million sale simplifies the investment case for dual-listed ResMed by exiting the somewhat peripheral vertical of aged care, and increasing its exposure to core franchises including sleep devices and masks. The divestment monetizes a mature asset and funds shareholder returns that should help support ResMed's share price, Jellinek tells clients. Morgans has a buy rating on ResMed's Australia-listed stock and a target price of 41.72 Australian dollars. Shares are down 0.3% at A$31.345. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 08, 2026 00:35 ET (04:35 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}